FIGURE 3. Case 3, p16 positive. Partial p16 staining with both p16 clones and >75% confluence of positive cells. A, G175-405 clone showing 26% to 50% of tumor cells with nuclear and cytoplasmic p16 expression (negative tumor outlined) and (B) >75% of the positive cells being confluent. C, E6H4 clone also showing 26% to 50% of tumor cells positive for p16 (negative tumor outlined) and (D) >75% confluence of the positive cells.
Abstract: Human papillomavirus-related oropharyngeal squamous cell carcinoma (OPSCC) has favorable prognosis relative to other head and neck squamous cell carcinomas. Criteria for predicting human papillomavirus status based upon p16 staining, including difficult cases with partial staining patterns, have been developed; however, clinical validation of these criteria and the clinical significance of partial p16 staining have not been reported. Eighty-one archival OPSCC cases were initially stained for p16 by immunohistochemistry with clone G175-405. The percentage of p16 + cells and percentage of confluence of p16 + cells were categorized as 25%, 26% to 75%, or >75%. Of all cases, 16 (20%) had partial p16 expression, with 26% to 75% p16 + cells. Applying previously developed criteria of >75% p16 + cells or >50% positive cells with >25% confluence, 48 (59%) patients were categorized p16 + and demonstrated expected clinical characteristics and superior disease-free survival and overall survival (P < 0.001) compared with p16 À patients. By themselves, the partial staining patients had intermediate outcomes; however, separating the partial staining cases by degree of confluence showed that those with >75% confluence had superior disease-free survival (P = 0.042). When the 16 original partial staining cases were re-stained with the alternative anti-p16 E6H4 clone, p16 status remained concordant for all cases, but only 3 of the 16 were interpreted as demonstrating partial staining. This report shows that the prevalence of partial p16 staining varies with the antibody utilized and clinically validates the application of a graded evaluation of both the number as well as confluence of positive cells for risk stratification of patients with OPSCC.
Key Words: human papillomavirus, oropharyngeal squamous cell carcinoma, p16 immunohistochemistry (Am J Surg Pathol 2016;40:1261-1269) I n recent decades, a variant of squamous cell carcinoma of the head and neck (HNSCC) has become apparent, which has distinct clinical ramifications and is associated with high-risk human papillomavirus (HPV). These HPVrelated oropharyngeal squamous cell carcinomas (OPSCC) have been shown to have a highly favorable clinical outcome despite an association with higher-stage regional metastatic disease. [1] [2] [3] [4] Epidemiologically, the incidence of HPV-related OPSCC has been increasing at a striking rate. 5, 6 Physicians differ on the appropriate methodology to diagnose HPV-related OPSCC. Some favor in situ hybridization for viral RNA or DNA, whereas others offer evidence that immunohistochemical (IHC) methods can serve as an efficient surrogate for direct detection of HPV. 7, 8 Carcinomas driven by HPV demonstrate overexpression of the p16 tumor-suppressor protein in response to oncogenic loss of control of the cell cycle. 9 Therefore, p16 staining of tumor tissue by IHC has been presented as a surrogate marker for HPV infection. Interestingly, p16 positivity has also been shown to identify good prognosis OPSCC independent of HPV status. 8 Interpretation of IHC staining for p16 in OPSCC is usually unequivocal, but a small proportion of cases may have partial staining. 10, 11 To set IHC staining thresholds for determining p16 positivity, and relating this positivity to high-risk HPV, Lewis et al 10 have proposed >75% p16-positive cells or presence of >50% p16-positive cells with >25% confluence (where confluence is defined as groups of 10 contiguous cells) as a criterion for predicting positive HPV status on the basis of correlation of these cutoffs with detection of transcriptionally active HPV. However, clinical validation of the partial staining criteria or the clinical significance of partial p16 staining has yet to be reported. Herein, we show that OPSCC cases with partial p16 staining have, as a group, intermediate clinical outcomes, between p16-positive and p16-negative cases, and this group can be appropriately risk stratified by further assessment of the confluence of staining. In addition, the proportion of partial staining cases appears to be dependent upon the anti-p16 antibody clone utilized.
MATERIALS AND METHODS
After obtaining Institutional Review Board approval, the University of Wisconsin Head and Neck Cancer Database was searched for consecutive patients with OPSCC treated with curative intent from 1990 to 2010. The oropharynx is defined here as the base of the tongue or tonsil, the soft palate, or adjacent posterior pharyngeal wall. Of these patients, 81 with archived tumor samples available at the University of Wisconsin Department of Pathology for review and additional p16 staining were included.
All 81 cases were studied by IHC staining performed on an automated platform (Ventana Medical Systems, Tucson, AZ) utilizing an antibody to p16 protein (BD Pharmingen, Purified mouse anti-human p16, Clone G175-405, 1:10 dilution) on archived formalinfixed paraffin-embedded tissue from surgical specimens. Antigen retrieval was accomplished by incubation with Cell Conditioning 1 reagent (Ventana Medical Systems) at 1001C for 52 minutes. Cases that were classified as partial staining were additionally stained with CINtec p16 Histology (Ventana Medical Systems, mouse anti-human p16, Clone E6H4, prediluted to an antibody concentration of 1.0 mg/mL and antigen retrieval with Cell Conditioning 1 reagent at 951C for 44 min). Positive staining was defined as visual detection of nuclear and cytoplasmic staining, with nuclear positivity defined as any appreciable shade of oxidized 3,3-diaminobenzidine beyond the baseline hematoxylin counter stain in the nuclei of neighboring nontumor cells. The percentage of p16-positive cells was semiquantitatively categorized into quartiles of r25%, 26% to 50%, 51% to 75%, and >75% by visual estimation at Â 200 magnification. Evaluation of confluence of p16 staining was introduced by Lewis et al 10 as a secondary criteria to determine which cases with 51% to 75% p16-positive cells harbored transcriptionally active HPV. In accordance to Lewis et al, 10 confluence in this study was defined as groups of 10 contiguous cells demonstrating staining and quantitated as the overall percentage of p16-positive cells that were in confluent groups assessed for their proportion of the overall amount of p16-positive cells and semiquantitatively categorized as r25%, 26% to 75%, or >75%. p16-positive cases were defined as those demonstrating >75% staining or >50% staining with >25% confluence. Assignment of cases into quartiles on the basis of the number of positive cells and confluence was performed by consensus (S.B. and D.T.Y.). Results of studies for p16 status were correlated with baseline clinical characteristics of the patients. Kaplan-Meier estimates of overall survival (OS) and disease-free survival (DFS) were calculated. Death was considered an event for OS with patients censored at the time of last follow-up. Any recurrence was considered an event for DFS calculation with patients censored at the time of death or last follow-up. The t test was used to compare means (2-tailed), whereas the w 2 test was performed for categorical variables (2-sided). Log-rank test was used for univariate analyses and Cox regression was performed for multivariate analysis. All statistical analyses were performed using IBM SPSS (Statistical Package for Social Sciences, version 22).
RESULTS
Anti-p16 Clone G175-405 Table 1 demonstrates the baseline clinical characteristics for the patients, categorized by p16 status as evaluated by the criteria described by Lewis et al. 10 Median follow-up of the patients was 3.4 years (maximum, 18.4 y). There were statistically significant differences in the age distribution, smoking status, and T and N classification between the 2 cohorts of patients. p16-positive cases were associated with younger age, less smoking history, lower T-stage, and higher N-stage at the time of diagnosis.
The categorization of cases by the number of p16 cells stained and percentage of confluence is shown in Table 2 . The proportion of specimens that demonstrated 26% to 50% or 51% to 75% p16-positive cells was 5% and 15%, respectively (16 cases total). These cases were combined to represent the partial p16 staining group. Correspondingly, cases with >75% p16-positive cells (Figs. 1A, B ) were deemed clearly p16 positive and those with r25% p16-positive cells (Figs. 1C, D) were deemed clearly p16 negative. In terms of confluence of staining, 63% of cases showed >75% confluence and 30% showed r25% confluence. Seven percent (6 cases) demonstrated 26% to 75% confluence. Examples of partial p16 staining with the G175-405 clone are presented in Figures 2-5 , alongside staining of the same cases with the E6H4 clone, which is further discussed below.
Five-year DFS rates for the case cohorts with r25%, 26% to 75%, and >75% p16-positive cells were 41%, 58%, and 81%, respectively (P < 0.001), with the partial staining cohort showing clinical outcomes that sit squarely between the good outcomes of the >75% cohort and the poor outcomes of the r25% cohort (Fig. 6A) . Interestingly, 5-year DFS for cases based on p16 confluence was 37%, 26%, and 77% for the r25%, 26% to 75%, and >75% cohorts, respectively (P < 0.001), suggesting that cases with 26% to 75% confluence had a similarly poor prognosis as those with <25% confluence (Fig. 6B ). As >75% confluence appears to be associated with good prognosis, we attempted to risk stratify the 16 cases with partial staining (between 26% and 75% p16positive cells) and intermediate outcomes (Fig. 6A ) by dichotomizing this cohort by whether or not they demonstrated >75% confluence (Fig. 6C ). We show that the partial staining cases with >75% confluence had significantly better DFS than those with <75% confluence (P = 0.042).
By applying the criteria proposed by Lewis and colleagues to the scored cases and categorizing cases as p16 positive if they demonstrated >75% p16-positive cells or >50% positive cells with >25% confluence, 48 (59%) patients were categorized as p16 positive and 33 (41%) as p16 negative ( Table 3 ). The 2-and 5-year DFS and OS for p16-positive patients was significantly better than those categorized as p16 negative, respectively (P < 0.001). Alternatively, we also applied the criteria of >75% p16-positive cells or 26% to 75% positive cells with >75% confluence for identifying p16-positive cases and show 51 (63%) patients being categorized as p16 positive and 30 (37%) as negative using these criteria ( Table 3 ). The 2-and 5-year DFS and OS for p16-positive patients was also significantly better than those labeled as p16 negative, respectively (P < 0.001).
On multivariate analysis for DFS, adjusting p16 status by baseline clinical characteristics, p16 status per Lewis criteria retained statistical significance (hazard ratio for failure in p16 negative, 3.6; 95% confidence interval: 1.1-12.0, P = 0.037), whereas T-stage classification retained borderline significance (hazard ratio for failure in T1or T2, 0.4; 95% confidence interval: 0.1-1.1, P = 0.067).
Anti-p16 Clone E6H4
The proportion of partial staining cases in this study (20%) was similar to that described by Chen et al 11 (35%) who also utilized the G175-405 clone in their study. However, Lewis et al 10 utilized the E6H4 clone, and the proportion of partial staining was <4%, suggesting that the G175-405 clone may be more susceptible to partial reactivity. Indeed, when we re-stained the 16 partial staining cases with the E6H4 clone, only 3 cases were categorized as partially stained (Table 4 ). Final determination of p16 status showed perfect concordance between the 2 clones. Cases 1 and 3 are examples in which partial staining was found with both clones, indicated by patches of p16-positive cells found in a background of p16-negative cells (Figs. 2, 3) . Because >75% of the positive cells in these cases were confluent, the cases were categorized as p16 positive. Case 12 (Fig. 4) is an example in which staining with clone G175-405 is interpreted as partial, because in some areas, many of the tumor cells lacked nuclear staining (Fig. 4A ), but in other areas, tumor cells showed nuclear and cytoplasmic staining, and >50% were confluent (Fig. 4B ). This same case stained with clone E6H4 clearly shows nuclear staining of all tumor cells, thereby negating the dilemma of partial staining (Figs. 4C, D and Table 4 ). Case 15 (Fig. 5) is an example in which staining with clone G175-405 is partial, showing scattered tumor cells with cytoplasmic and variable nuclear staining that are not confluent (Figs. 5A, B) , hence the case is classified as p16 negative. However, no partial staining is evident with clone E6H4 (Figs. 5C, D) , and the case can be directly classified as p16 negative (Table 4 ).
DISCUSSION
Evaluation of p16 staining on formalin-fixed paraffin-embedded tumor specimens to categorize OPSCC cases as p16 positive or negative is prognostically relevant. Clinicians routinely discuss p16 results with HNSCC patients as they review anticipated treatment outcomes. However, determining whether cases are p16 positive or negative can be difficult in the small proportion of cases that demonstrate a partial staining pattern. Lewis et al 10 have shown that for these cases, the presence of >50% p16-positive cells with >25% confluence is associated with transcriptionally active HPV and recommend this criterion as a cutoff for defining p16 positivity. We clinically validated this criterion in a retrospective cohort of 81 patients with OPSCC, 20% of whom demonstrated partial p16 staining, with between 26% and 75% of tumor cells demonstrating p16 expression after staining with the G175-405 clone. After dichotomizing all cases as p16 positive or negative on the basis of Lewis and colleagues, at a median follow-up of 3.4 years, both DFS and OS were superior in p16-positive patients (P < 0.001) ( Table 3 ). The clinical characteristics of the dichotomized patients were as expected, with the p16-positive patients tending to by younger with less smoking history and presenting with smaller primary tumors but more advanced regional metastases ( Table 1) .
As anticipated, DFS for patients with >75% p16positive cells in their tumors was superior to those with r25% p16-positive cells, but, interestingly, the DFS curve for the partial staining cases with 26% to 75% positive cells fell between the other 2 curves (Fig. 6A ). This suggests that cases with partial p16 staining have intermediate outcomes and likely comprise a mixture of p16-positive and p16-negative patients. In accordance to Lewis et al, 10 we assessed confluence of p16 staining as an additional discriminator. After scoring the confluence of p16 staining in all 81 cases as <25%, 25% to 75%, or >75%, we show that cases with >75% confluence had superior outcomes compared with those with r75% confluence (Fig. 6B) . Surprisingly, the 6 cases with between 25% and 75% confluence did not have an intermediate outcome; rather, they had a 5-year DFS of 26%, similar to that of the r25% confluence group (37% 5-y DFS). Accordingly, the results suggest that >75% confluence is associated with superior outcomes; hence, it may be reasonable to consider partial p16 staining cases with >75% confluence as p16 positive. Indeed when the 16 partial-staining cases are dichotomized by confluence, the cases with >75% confluence have superior DFS compared with those that do not (Fig. 6C) .
Overall, the findings support the notion that assessment of confluence of p16 staining can be a useful and clinically relevant discriminator of p16 status in cases with partial p16 staining. On the basis of our findings, we investigated the application of modified discriminating criteria, defining p16-positive cases as >75% p16 positivity or 25% to 75% positivity with >75% confluence. Applying these criteria to the study cohort resulted in 51 patients being classified as p16 positive and 30 as negative, compared with 48 and 33, respectively, on the basis of Lewis and colleagues ( Table 3) . The low number of partial staining cases and the challenge of overfitting limited our ability to compare the performance of the 2 methodologies, which will require additional studies on an independent patient cohort. However, 2-year DFS and OS in the p16-positive cases determined by the Lewis criteria were slightly higher than the modified criteria ( Table 3 ), suggesting that the modified criteria may not improve accuracy.
We also found that the proportion of partial staining is likely dependent upon the antibody clone utilized. The G175-405 clone generally showed weaker staining, especially in the tumor cell nuclei, similar to Chen et al's 11 previous report. The E6H4 clone showed more robust nuclear and cytoplasmic costaining, boosting the number of p16-positive tumor cells to >75% in many of the same cases that showed <75% positive tumor cells with the G175-405 clone ( Table 4 ). Of the 16 cases that showed partial staining with G175-405, only 3 showed partial staining with E6H4, and all 3 were deemed p16 positive on the basis of almost 100% confluence of positive cells (Figs. 2, 3) . Interestingly, E6H4 also appears to be more specific than G175-405, wherein G175-405 partial staining cases deemed p16 negative due to a lack of confluence were unequivocally p16 negative with hardly a single p16positive cell when stained with E6H4 (Table 4 and Fig. 5 ). In terms of final determination of p16 status (positive or negative) for the partial staining cases, no discordance between the clones was found ( Table 4 ). Caution needs to be used when assessing patchy p16 positivity in isolated cells. p16 overexpression in isolated cells is a nonspecific finding, and irregular, scanty p16 staining in HNSCCs that occur outside of the oropharynx may not correlate with either HPV or a good prognosis. However, in the cervix 12 and in the oropharynx, 10 strong, block-like IHC staining for p16 with >75% of positive cells stained in contiguity correlates well with the presence of HPV.
In recent years, systematic evaluation of factors that influence outcome in oropharynx cancer patients has revealed several interesting findings. For example, each additional pack-year of tobacco smoking increases the risk of death. This factor serves to lower the favorable outcome for HPV-positive OPSCC patients who are heavy smokers, quite close to the level of HPV-negative patients. 1 Although some have postulated that the introduction of intensity-modulated radiation therapy in the early 2000s may be responsible for increasing tumor control rates in OPSCC, detailed studies suggest that other factors may explain this outcome improvement (including the increased prevalence of HPV-positive tumors) as opposed to the use of intensity-modulated radiation therapy. 13 These type of findings underscore the importance of detailed clinical outcome validation studies that carefully examine the relationship between new biomarkers, treatment techniques, and population outcomes for individual cancers.
In summary, p16 positivity in OPSCC is associated with longer DFS, and the improved outcomes are likely related to carcinogenesis driven by high-risk HPV. 1, 2, 4, 9 Criteria used to evaluate p16 IHC staining should include the percentage of cells stained as well as the confluence of staining, as the combination of these criteria described by Lewis et al, 10 >75% p16 + cells or >50% positive cells with >25% confluence, can discriminate those cases with transcriptionally active HPV infection. Until now, these findings and the proposed criteria had not been validated by patient outcomes. We show that application of the criteria proposed by Lewis and colleagues, or a modified version of the criteria (>75% p16 positivity or 25% to 75% positivity with >75% confluence) can effectively risk stratify a cohort of 81 OPSCC cases into 2 prognostically relevant p16-positive and p16-negative groups. We also show that the proportion of partial staining cases is likely dependent upon the antibody clone utilized with many of the partial staining cases identified by clone G175-405 showing clear positivity or negativity when restained with clone E6H4. 
